Patents by Inventor Yuwadee TALAWANICH

Yuwadee TALAWANICH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • cell line with thyA knockout, folA knockout, and one or both of folP knockout, and folK knockout
    Patent number: 10011842
    Abstract: In this invention, cell lines are created for enzyme inhibitory testing of inhibitors against Plasmodium falciparum DHFR-TS and HPPK-DHPS. Provided the complementing DHFR-TS and HPPK-DHPS have sufficient activities to support growth of the surrogates in un-supplemented medium, the same surrogates could be used for screening inhibitors of targets against other parasite and pathogen species e.g. Plasmodium vivax, Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii or Mycobacterium tuberculosis. The cell lines in this invention are Escherichia coli strain whose thyA, folA, folK, and folP genes were disrupted using genetic knockout coupled with elimination of antibiotic resistance markers. The thyA KO, folP KO, folK KO, thyAfolA KO, folKfolP KO, thyAfolAfolP KO, thyAfolAfolK KO and thyAfolAfolKfolP KO E.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: July 3, 2018
    Assignee: National Science and Technology Development Agency
    Inventors: Nattida Suwanakitti, Yuwadee Talawanich, Yongyuth Yuthavong, Sumalee Kamchonwongpaisan
  • A BACTERIAL SURROGATE FOR TESTING OF ANTIMALARIALS: THYA KNOCKOUT, FOLA KNOCKOUT, FOLP KNOCKOUT, AND FOLK KNOCKOUT BACTERIA FOR TESTING OF INHIBITION OF ANTIFOLATE PATHWAY
    Publication number: 20160230178
    Abstract: In this invention, cell lines are created for enzyme inhibitory testing of inhibitors against Plasmodium falciparum DHFR-TS and HPPK-DHPS. Provided the complementing DHFR-TS and HPPK-DHPS have sufficient activities to support growth of the surrogates in un-supplemented medium, the same surrogates could be used for screening inhibitors of targets against other parasite and pathogen species e.g. Plasmodium vivax, Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii or Mycobacterium tuberculosis. The cell lines in this invention are Escherichia coli strain whose thyA, folA, folK, and folP genes were disrupted using genetic knockout coupled with elimination of antibiotic resistance markers. The thyA KO, folP KO, folK KO, thyAfolA KO, folKfolP KO, thyAfolAfolP KO, thyAfolAfolK KO and thyAfolAfolKfolP KO E.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 11, 2016
    Applicant: National Science And Technology Development Agency
    Inventors: Nattida SUWANAKITTI, Yuwadee TALAWANICH, Yongyuth YUTHAVONG, Sumalee KAMCHONWONGPAISAN